ClinicalTrials.gg
Active, not recruitingNCT07005128DeLLphi-312Updated Sep 8, 2026

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

A Phase 3 interventional study of Tarlatamab and Durvalumab in Small-cell Lung Cancer and Extensive Stage Small-cell Lung Cancer, sponsored by Amgen. Active, not recruiting at 164 sites in 26 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing AMG 757 in Small Cell Lung Carcinoma — 9 open to participants now, 17 under way, 6 of them phase 3. AMG 757 · Small Cell Lung Carcinoma.

Enrollment
6th of 18
350 · median 221
Started
2025
with 4 others
Phase 3
6 of 18
2 open now
Primary completion
2029-01
later than 9 of 16 live
Registered
10th of 18
by date
Lead sponsor
11 of 18
Amgen

Among the 18 studies testing AMG 757 in Small Cell Lung Carcinoma, this one is the 6th largest by enrollment, is one of 5 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 9 of the 16 other live ones, and was the 10th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 18 studies testing AMG 757 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About AMG 757

AMG 757: first FDA approval 2024 (IMDELLTRA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing AMG 757 in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

03

Conditions studied

  • Small-cell Lung Cancer
  • Extensive Stage Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided before initiation of any study-specific activities/procedures.
  • Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.
  • or cytologically documented ES-SCLC (American Joint Committee on Cancer, 2017, Stage IV SCLC [T any, N any, M1 a/b/c]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.
  • as defined per 1.1.
  • Suitable to receive carboplatin, etoposide and durvalumab regimen as treatment per investigator clinical assessment.
  • Minimum ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Participants can have no history of other in the last 2 years.
  • Any symptomatic central nervous system (CNS) , or .
  • They will have no history of severe or life-threatening events to immune-mediated therapy.
  • History of arterial thrombosis (eg, stroke or ) within 6 months prior to first dose of study treatment.
  • They will have no active or inflammatory disorders.
  • Presence of active (HIV) or active Hepatitis (B/C) infection.
  • Evidence or interstitial lung disease (ILD) or active, non-infectious pneumonitis.
  • History of solid organ transplant.
  • They will not have had a myocardial infarction and/or symptomatic congestive heart failure ( > class II) within 6 months prior to first dose of study treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    Tarlatamab + Durvalumab + Carboplatin + Etoposide

    Participants will receive tarlatamab in combination with durvalumab, carboplatin and etoposide for 4 cycles followed by tarlatamab and durvalumab.

    Drug: Tarlatamab · Drug: Durvalumab · Drug: Carboplatin · Drug: Etoposide

  • Active comparator
    Durvalumab + Carboplatin + Etoposide

    Participants will receive durvalumab, carboplatin and etoposide for 4 cycles followed by durvalumab.

    Drug: Durvalumab · Drug: Carboplatin · Drug: Etoposide

Interventions

  • Tarlatamab will be administered as an intravenous (IV) infusion.

    Also known as: AMG 757, Imdelltra

  • Durvalumab will be administered as an IV infusion.

  • Carboplatin will be administered as an IV infusion.

  • Etoposide will be administered as an IV infusion.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 3.5 years

  2. Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)

    Time frame: Up to approximately 3.5 years

Secondary outcomes

  1. PFS (Investigator Assessed)

    Time frame: Up to approximately 4 years

  2. Objective Response (OR)

    Time frame: Up to approximately 4 years

  3. Disease Control

    Time frame: Up to approximately 4 years

  4. Duration of Response (DOR)

    Time frame: Up to approximately 4 years

  5. PFS Rate

    Time frame: 6 months, 1 year, and 2 years

  6. OS Rate

    Time frame: 6 months, 1 year, 2 years and 3 years

  7. Time to Progression

    Time frame: Up to approximately 4 years

  8. Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 4 years

  9. Number of Participants Who Experience Treatment-related Adverse Events

    Time frame: Up to approximately 4 years

  10. Number of Participants Who Experience Events of Interest

    Time frame: Up to approximately 4 years

  11. Serum Concentrations of Tarlatamab

    Time frame: Up to approximately 1 year

  12. Number of Participant Who Develop Anti-Tarlatamab Antibodies

    Time frame: Up to 13 months

07

Study locations

164 sites

Showing the first 100 of 164 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2029, 40 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 40 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 5, 2025
StartActual
Aug 18, 2025
Primary completionEst.
Jan 4, 2029
CompletionEst.
Aug 15, 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07005128
Lead sponsor
Amgen
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Aug 18, 2025
Primary completion
Jan 4, 2029 (estimated)
Completion
Aug 15, 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMG 757

Start the discussion